OncoMatch

OncoMatch/Clinical Trials/NCT01185132

Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy

Is NCT01185132 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for breast cancer.

Phase 3RecruitingRocky Mountain Cancer CentersNCT01185132Data as of May 2026

In the setting of radiotherapy as part of breast-conservation therapy for patients with early stage breast cancer, the novel planning and delivery method of intensity modulated radiotherapy is an effective and safe alternative to the commonly-used standard 3D-conformal external beam radiotherapy, spares more normal breast and lung tissue, and may lead to improved clinical outcomes.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Disease stage

Required: Stage TIS (AJC)

Grade: high nuclear grade DCIS

Histologically confirmed disease (AJC Classification): Tis, T1, T2 (≤ 3.0 cm), N0, M0.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Rocky Mountain Cancer Centers - Aurora · Aurora, Colorado
  • Rocky Mountain Cancer Centers - Boulder · Boulder, Colorado
  • Rocky Mountain Cancer Centers - Lakewood · Lakewood, Colorado
  • Rocky Mountain Cancer Centers - Littleton · Littleton, Colorado
  • Rocky Mountain Cancer Centers - Thornton · Thornton, Colorado

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify